Christian M. Hoelscher

Christian M. Hoelscher

Neurosurgery

445 Hurffville Cross Keys Road
Suite B16
Sewell, NJ 08080

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 183 publications

GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer's and Parkinson's disease.

GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer's and Parkinson's disease.

Journal: Frontiers in neuroscience

Published: June 11, 2026

Semaglutide showed limited improvements in patients with Alzheimer's disease: Revisiting the evoke and evoke + clinical trials.

Semaglutide showed limited improvements in patients with Alzheimer's disease: Revisiting the evoke and evoke + clinical trials.

Journal: Journal of Alzheimer's disease : JAD

Published: June 09, 2026

P1642-1, a novel pancreatic polypeptide analogue, ameliorates cognitive impairment in 5 ×FAD mice and is associated with enhanced PINK1/Parkin-related mitophagy.

P1642-1, a novel pancreatic polypeptide analogue, ameliorates cognitive impairment in 5 ×FAD mice and is associated with enhanced PINK1/Parkin-related mitophagy.

Journal: Peptides

Published: March 31, 2026

The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.

The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.

Journal: Frontiers in endocrinology

Published: March 07, 2026

A novel bifunctional peptide predicted to target neuropeptide Y4 and GLP-1 receptors alleviates cognitive deficits in 5 × FAD mice by modulating cGAS-STING-mediated neuroinflammation.

A novel bifunctional peptide predicted to target neuropeptide Y4 and GLP-1 receptors alleviates cognitive deficits in 5 × FAD mice by modulating cGAS-STING-mediated neuroinflammation.

Journal: Biochemical pharmacology

Published: February 25, 2026

Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease.

Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease.

Journal: Peptides

Published: January 12, 2026

A food-medicine homology formulation ameliorates atherosclerosis by attenuating dyslipidemia and inflammation via the PI3K/Akt/NF-κB pathway.

A food-medicine homology formulation ameliorates atherosclerosis by attenuating dyslipidemia and inflammation via the PI3K/Akt/NF-κB pathway.

Journal: Frontiers in pharmacology

Published: September 22, 2025

Targeting atherosclerosis with medicine and food homology substances: Mechanistic insights and application strategies.

Targeting atherosclerosis with medicine and food homology substances: Mechanistic insights and application strategies.

Journal: Journal of ethnopharmacology

Published: September 14, 2025

Development of an explainable machine learning model for predicting poststroke anxiety: A multicenter study using Shapley Additive Explanations and nomogram visualization.

Development of an explainable machine learning model for predicting poststroke anxiety: A multicenter study using Shapley Additive Explanations and nomogram visualization.

Journal: Digital health

Published: June 27, 2025

Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.

Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.

Journal: Nature medicine

Published: June 17, 2025

Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies.

Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies.

Journal: CNS drugs

Published: May 22, 2025

The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson's disease with diabetes co-morbidity.

The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson's disease with diabetes co-morbidity.

Journal: Frontiers in neuroscience

Published: March 19, 2025

Showing 1-12 of 183

Last Updated: 09/26/2026